ライフサイエンスコーパス: brief psychiatric rating scale

1 overall clinical symptoms as measured by the Brief Psychiatric Rating Scale.

2 disturbance, and total score measured on the Brief Psychiatric Rating Scale.

3 e rated at admission by physicians using the Brief Psychiatric Rating Scale.

4 easured through monthly assessments with the Brief Psychiatric Rating Scale.

5 sed on the psychotic symptom subscale of the Brief Psychiatric Rating Scale, a Clinical Global Impres

6 n analysis of variance (ANOVA) comparison of Brief Psychiatric Rating Scale-Anchored (BPRS-A) total c

7 rimary efficacy measures were improvement in Brief Psychiatric Rating Scale and Clinical Global Impre

8 sening (compared with baseline) on the total Brief Psychiatric Rating Scale and the Clinical Global I

9 s of movement disorders, psychiatric status (Brief Psychiatric Rating Scale), and functioning (Global

10 demographic variables, generalized symptoms (Brief Psychiatric Rating Scale), and positive and negati

11 ding the MMSE, the cognitive subscale of the Brief Psychiatric Rating Scale, and a cognitive summary

12 ale for the Assessment of Negative Symptoms, Brief Psychiatric Rating Scale, and Clinical Global Impr

13 chiatric Rating Scale, method of scoring the Brief Psychiatric Rating Scale, and date of publication

14 um of selected positive symptom items of the Brief Psychiatric Rating Scale, and for the Clinical Glo

15 ize and scores on the Mini-Mental State, the Brief Psychiatric Rating Scale, and the antipsychotic dr

16 -Administered Dissociative States Scale, the Brief Psychiatric Rating Scale, and the Young Mania Rati

17 Their symptoms were evaluated with the Brief Psychiatric Rating Scale at baseline and follow-up

18 ty (Premorbid Assessment Scale, P = .06) and Brief Psychiatric Rating Scale at follow-up (P = .07).

19 athology and functioning, as assessed by the Brief Psychiatric Rating Scale (BPRS) (range, 24-168), S

20 superior to that of haloperidol on the total Brief Psychiatric Rating Scale (BPRS) after the first 4

21 The primary outcome measures were the Brief Psychiatric Rating Scale (BPRS) and Clinical Globa

22 The Brief Psychiatric Rating Scale (BPRS) and Clinical Globa

23 gy was assessed at 2-week intervals with the Brief Psychiatric Rating Scale (BPRS) and the Scale for

24 e Assessment of Negative Symptoms (SANS) and Brief Psychiatric Rating Scale (BPRS) assessed clinical

25 Patients whose scores on the Brief Psychiatric Rating Scale (BPRS) failed to improve

26 f Changes, olanzapine and risperidone on the Brief Psychiatric Rating Scale (BPRS) hostile suspicious

27 Brief Psychiatric Rating Scale (BPRS) ratings were obtai

28 Brief Psychiatric Rating Scale (BPRS) ratings were obtai

29 nventory-II and visual analogue mood scales, Brief Psychiatric Rating Scale (BPRS) score, and both se

30 assessed using the mean of time 1 and time 2 Brief Psychiatric Rating Scale (BPRS) scores and the per

31 Brief Psychiatric Rating Scale (BPRS) scores were analyz

32 cally significantly greater reduction in the Brief Psychiatric Rating Scale (BPRS) total and negative

33 sessment of Negative Symptoms (SANS) and the Brief Psychiatric Rating Scale (BPRS) were used to asses

34 Outcome measures were the Brief Psychiatric Rating Scale (BPRS), Repeatable Batter

35 yndrome Scale (PANSS) for schizophrenia, the Brief Psychiatric Rating Scale (BPRS), the Clinical Glob

36 inally over the course of the study with the Brief Psychiatric Rating Scale (BPRS), the Young Mania R

37 tal score and psychosis cluster score on the Brief Psychiatric Rating Scale (BPRS).

38 baseline to endpoint in total scores on the Brief Psychiatric Rating Scale (BPRS).

39 ain their attitudes toward admission and the Brief Psychiatric Rating Scale (BPRS).

40 ks with the Young Mania Rating Scale and the Brief Psychiatric Rating Scale (BPRS).

41 Patients received monthly ratings on the Brief Psychiatric Rating Scale, Clinical Global Impressi

42 Outcome measures included the Brief Psychiatric Rating Scale, Clinician-Administered D

43 hensive Assessment of At-Risk Mental States, Brief Psychiatric Rating Scale/Comprehensive Assessment

44 task were not related to total scores on the Brief Psychiatric Rating Scale factor 1 or on the Though

45 change from baseline to week 4 on the total Brief Psychiatric Rating Scale favored placebo (i.e., -8

46 eline and within-arm end point change in the Brief Psychiatric Rating Scale, method of scoring the Br

47 <.001); negative symptoms as assessed by the Brief Psychiatric Rating Scale negative symptoms subscal

48 Symptoms were measured by the Brief Psychiatric Rating Scale or by the identical items

49 cebo response, based on change scores on the Brief Psychiatric Rating Scale or the Positive and Negat

50 were detected in negative symptoms using the Brief Psychiatric Rating Scale or the Schedule for Asses

51 ated significant improvement in score on the Brief Psychiatric Rating Scale over time with both medic

52 he not carried forward analysis on the total Brief Psychiatric Rating Scale (P < .03), for not carrie

53 symptoms of schizophrenia as assessed by the Brief Psychiatric Rating Scale positive symptoms subscal

54 se haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on p

55 Activations correlated with Brief Psychiatric Rating Scale psychosis scores.

56 RBANS performance minimally correlated with Brief Psychiatric Rating Scale ratings but was strongly

57 nd correlations with symptom severity (total Brief Psychiatric Rating Scale score) were examined.

58 easure of negative symptoms derived from the Brief Psychiatric Rating Scale (that measured both prima

59 Other assessments used the Brief Psychiatric Rating Scale, the Clinical Global Impr

60 Subjects were assessed using the Brief Psychiatric Rating Scale, the Hamilton Depression

61 he Mini-Mental State Examination (MMSE), the Brief Psychiatric Rating Scale, the Scale for the Assess

62 Clinical evaluations with the Brief Psychiatric Rating Scale, the Scale for the Assess

63 The primary outcome measures were Brief Psychiatric Rating Scale total score and positive

64 s had significant differences in the 18-item Brief Psychiatric Rating Scale total score and subscale

65 was defined as a 50% reduction of either the Brief Psychiatric Rating Scale total score or Positive a

66 group, patients were also recruited if their Brief Psychiatric Rating Scale total score was higher th

67 han a typical antipsychotic, as reflected by Brief Psychiatric Rating Scale total score, categorical

68 drugs on two measures of negative symptoms, Brief Psychiatric Rating Scale total scores, and depress

69 Psychotic symptom subscores from the Brief Psychiatric Rating Scale were selectively correlat

70 esponse to amphetamine was measured with the Brief Psychiatric Rating Scale, Young Mania Rating Scale